[1] THRIFT A P, EL-SERAG H B. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol, 2020, 18(3):534-542. [2] 申伟松, 李佶阳, 崔建新, 等. 胃癌肝转移手术治疗预后的Meta分析[J]. 中华胃肠外科杂志, 2014, 17(2):128-132. [3] SUNDARARAJ S, RAVINDRAN A, CASAROTTO M G. AHNAK: the quiet giant in calcium homeostasis[J]. Cell Calcium, 2021, 96:102403. [4] BADER J E, VOSS K, RATHMELL J C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy[J]. Mol Cell, 2020, 78(6):1019-1033. [5] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658. [6] LI T, FU J, ZENG Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020,48(W1):W509-W514. [7] NAGY A, MUNKACSY G, GYORFFY B. Pancancer survival analysis of cancer hallmark genes[J]. Sci Rep, 2021,11(1):6047. [8] TIE J, PAN Y, ZHAO L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor[J]. PLoS Genet, 2010, 6(3):e1000879. [9] ARNETH B. Tumor microenvironment[J]. Medicina: Kaunas, 2019, 56(1):15. [10] WU R S, LIN J, XING Y M, et al. OVOL2 inhibits macrophage M2 polarization by regulating IL-10 transcription, and thus inhibits the tumor metastasis by modulating the tumor microenvironment[J]. Immunol Lett, 2022, 242:17-26. [11] ZHENG M, LIU J, BIAN T, et al. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma[J]. Int Immunopharmacol, 2021,90:107134. |